Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials

Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials

Abstract p53, encoded by the tumor suppressor gene TP53, is one of the most important tumor suppressor factors in vivo and can be negatively regulated by MDM2 through p53–MDM2 negative feedback loop. Abnormal p53 can be observed in almost all tumors, mainly including p53 mutation and functional inac...

Full description

Bibliographic Details
Main Authors: Haohao Zhu, Hui Gao, Yingying Ji, Qin Zhou, Zhiqiang Du, Lin Tian, Ying Jiang, Kun Yao, Zhenhe Zhou
Format: Article
Language:English
Published: BMC 2022-07-01
Series:Journal of Hematology & Oncology
Subjects:
p53
MDM2
Inhibitor
Multi-target
Degrader
Online Access:https://doi.org/10.1186/s13045-022-01314-3

Internet

https://doi.org/10.1186/s13045-022-01314-3

Similar Items